We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can CAH's Surging Other Growth Businesses Become Its Next Profit Engine?
Read MoreHide Full Article
Key Takeaways
Cardinal Health's Other Growth Businesses revenues rose 34% to $1.7 billion in fiscal Q3.
CAH saw NPHS growth fueled by theranostics demand and At-Home Solutions expansion.
CAH's OptiFreight revenues rose nearly 20%, boosting higher-margin growth exposure.
Cardinal Health’s (CAH - Free Report) fiscal third-quarter results suggest that the company’s “Other Growth Businesses” are evolving from complementary assets into a meaningful profit engine, underscoring management’s strategy to diversify beyond its traditionally low-margin pharmaceutical distribution business.
In the third quarter of fiscal 2026, revenues from the segment surged 34% to $1.7 billion, while segment profit climbed at an even faster rate of 52%, highlighting the increasing earnings leverage of these higher-margin operations.
The momentum was broad-based, with strength coming from Nuclear and Precision Health Solutions (NPHS), At-Home Solutions and OptiFreight Logistics. NPHS continued to benefit from rapid adoption of theranostics, where revenues gained more than 30%, supported by Cardinal Health’s investments in isotope production capabilities and rising demand for targeted cancer therapies. Management emphasized growing engagement with pharmaceutical innovators, which includes the Actinium-225 platform that is already supporting more than 15 clinical trials globally.
At-Home Solutions is benefiting from the secular shift of healthcare services toward home-based care. Demand remained strong, aided by the successful integration of the Advanced Diabetes Supply (ADS) acquisition. Cardinal Health has now onboarded nearly 500,000 new patients and about 1,000 employees. The company is also migrating ADS volumes into its distribution centers, creating scale efficiencies and a stronger chronic-care platform. The business is also generating synergies with pharma through its ContinuCare Pathway program, which now serves 165,000 patients.
OptiFreight Logistics added another layer of growth, with revenues increasing nearly 20%, reflecting rising demand for cost-efficient healthcare logistics solutions. Together, these businesses are not only diversifying Cardinal Health’s revenue mix but also expanding exposure to faster-growing, higher-margin healthcare niches — potentially making them an increasingly important driver of long-term profitability.
Peer Update
Align Technology’s (ALGN - Free Report) future growth appears increasingly tied to deeper penetration of digital orthodontics and improved operating leverage. In the first quarter of 2026, the company reported record clear aligner shipments of 686,000 cases, supported by double-digit growth in international markets, especially APAC, EMEA and Latin America, while North America stabilized.
Future demand drivers for ALGN include expanding adoption among teens and children through products such as Invisalign First and Palatal Expander. Apart from product adoption, growing DSO partnerships, and financing initiatives are improving affordability and case conversion. Align Technology’s profitability is likely to be driven by AI-enabled treatment planning, lower refinement rates, operational efficiencies and higher-margin product configurations requiring fewer aligners, supporting sustained margin expansion.
CONMED’s (CNMD - Free Report) long-term growth and profitability outlook is likely to be driven by its focused portfolio strategy and higher-margin surgical platforms. Following the strategic divestiture of its gastroenterology business, management is concentrating resources on AirSeal, Buffalo Filter and BioBrace, which target attractive growth categories in the healthcare segment.
AirSeal should benefit from increasing robotic and laparoscopic surgeries, where penetration is still low. The U.S. laparoscopic procedures exceed 3 million annually, representing significant growth opportunity. Buffalo Filter has a favorable tailwind from expanding smoke-free operating room legislation, while BioBrace adoption continues to strengthen as surgeons embrace biologic soft-tissue repair solutions. Improving supply-chain reliability and a richer product mix should also support margin expansion and profit recovery.
CAH’s Price Performance, Valuation and Estimates
Shares of CAH have lost 2.4% so far this year compared with the industry’s 8.2% decline.
Image Source: Zacks Investment Research
From a valuation standpoint, Cardinal Health trades at a forward price-to-earnings ratio of 16.98, above the industry average. It is also higher than its five-year median of 13.72. CAH carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Cardinal Health’s fiscal 2026 earnings implies a 30.1% rise from the year-ago period’s level, followed by 11.4% expected growth in fiscal 2027.
View the Zacks #1 Rank List
Image: Bigstock
Can CAH's Surging Other Growth Businesses Become Its Next Profit Engine?
Key Takeaways
Cardinal Health’s (CAH - Free Report) fiscal third-quarter results suggest that the company’s “Other Growth Businesses” are evolving from complementary assets into a meaningful profit engine, underscoring management’s strategy to diversify beyond its traditionally low-margin pharmaceutical distribution business.
In the third quarter of fiscal 2026, revenues from the segment surged 34% to $1.7 billion, while segment profit climbed at an even faster rate of 52%, highlighting the increasing earnings leverage of these higher-margin operations.
The momentum was broad-based, with strength coming from Nuclear and Precision Health Solutions (NPHS), At-Home Solutions and OptiFreight Logistics. NPHS continued to benefit from rapid adoption of theranostics, where revenues gained more than 30%, supported by Cardinal Health’s investments in isotope production capabilities and rising demand for targeted cancer therapies. Management emphasized growing engagement with pharmaceutical innovators, which includes the Actinium-225 platform that is already supporting more than 15 clinical trials globally.
At-Home Solutions is benefiting from the secular shift of healthcare services toward home-based care. Demand remained strong, aided by the successful integration of the Advanced Diabetes Supply (ADS) acquisition. Cardinal Health has now onboarded nearly 500,000 new patients and about 1,000 employees. The company is also migrating ADS volumes into its distribution centers, creating scale efficiencies and a stronger chronic-care platform. The business is also generating synergies with pharma through its ContinuCare Pathway program, which now serves 165,000 patients.
OptiFreight Logistics added another layer of growth, with revenues increasing nearly 20%, reflecting rising demand for cost-efficient healthcare logistics solutions. Together, these businesses are not only diversifying Cardinal Health’s revenue mix but also expanding exposure to faster-growing, higher-margin healthcare niches — potentially making them an increasingly important driver of long-term profitability.
Peer Update
Align Technology’s (ALGN - Free Report) future growth appears increasingly tied to deeper penetration of digital orthodontics and improved operating leverage. In the first quarter of 2026, the company reported record clear aligner shipments of 686,000 cases, supported by double-digit growth in international markets, especially APAC, EMEA and Latin America, while North America stabilized.
Future demand drivers for ALGN include expanding adoption among teens and children through products such as Invisalign First and Palatal Expander. Apart from product adoption, growing DSO partnerships, and financing initiatives are improving affordability and case conversion. Align Technology’s profitability is likely to be driven by AI-enabled treatment planning, lower refinement rates, operational efficiencies and higher-margin product configurations requiring fewer aligners, supporting sustained margin expansion.
CONMED’s (CNMD - Free Report) long-term growth and profitability outlook is likely to be driven by its focused portfolio strategy and higher-margin surgical platforms. Following the strategic divestiture of its gastroenterology business, management is concentrating resources on AirSeal, Buffalo Filter and BioBrace, which target attractive growth categories in the healthcare segment.
AirSeal should benefit from increasing robotic and laparoscopic surgeries, where penetration is still low. The U.S. laparoscopic procedures exceed 3 million annually, representing significant growth opportunity. Buffalo Filter has a favorable tailwind from expanding smoke-free operating room legislation, while BioBrace adoption continues to strengthen as surgeons embrace biologic soft-tissue repair solutions. Improving supply-chain reliability and a richer product mix should also support margin expansion and profit recovery.
CAH’s Price Performance, Valuation and Estimates
Shares of CAH have lost 2.4% so far this year compared with the industry’s 8.2% decline.
Image Source: Zacks Investment Research
From a valuation standpoint, Cardinal Health trades at a forward price-to-earnings ratio of 16.98, above the industry average. It is also higher than its five-year median of 13.72. CAH carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Cardinal Health’s fiscal 2026 earnings implies a 30.1% rise from the year-ago period’s level, followed by 11.4% expected growth in fiscal 2027.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.